^
    Back
    Association details:
    Biomarker:NRAS overexpression
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Nature
    Title:

    Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

    Excerpt:
    Flag–N-RAS(Q61K) stable overexpression conferred PLX4032 resistance in the M249 parental cell line….Overexpression of PDGFRβ or N-RAS(Q61K) conferred PLX4032 resistance to PLX4032-sensitive parental cell lines.
    DOI:
    10.1038/nature09626
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes

    Excerpt:
    In agreement, we found that overexpression of NRASV12 in A375 cells made them refractory to the anti-proliferative effect of the BRAF inhibitor PLX-4032. Contrarily, these cells remained sensitive to inhibition by DEL-22379.
    DOI:
    https://doi.org/10.1016/j.ccell.2015.07.001